Johnson & Johnson’s Acquisition of Ci:z Holdings Co., Ltd
October 24, 2018
On October 23, 2018, Johnson & Johnson announced that it has agreed with Ci:z Holdings Co., Ltd. (the “Company”), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all‑cash offer to acquire all of the outstanding shares of the Company not already held by Johnson & Johnson and its affiliates for approximately ¥230 billion. The acquisition will include the Company’s range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skincare products. Cravath is representing Johnson & Johnson in connection with the transaction.
The Cravath team is led by partner Robert I. Townsend III and includes associate Aashim Usgaonkar on M&A matters, and partner J. Leonard Teti II and associate Andrew T. Davis on tax matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1990, Harvard Law Schoolmagna cum laude
-
A.B., 1987, Harvard Collegemagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2005, University of Virginia School of LawOrder of the Coif
-
A.B., 1999, Princeton Universitywith Honors
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 12, 2025
Johnson & Johnson’s $5 Billion Registered Notes Offering and Concurrent €4 Billion Notes Offering
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
